{"id":15675,"date":"2025-06-21T10:23:00","date_gmt":"2025-06-21T04:53:00","guid":{"rendered":"https:\/\/www.jbsagolf.com\/blogs\/?p=15675"},"modified":"2025-10-27T08:13:28","modified_gmt":"2025-10-27T08:13:28","slug":"newffr-intaspharma","status":"publish","type":"post","link":"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/","title":{"rendered":"NewFFR IntasPharma: A Deep Dive into Intas\u2019s FFR Platform"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">NewFFR IntasPharma is an innovative contract clinical research and manufacturing unit that is the division of an Indian pharma giant, Intas Pharmaceuticals, which has an international presence. This division is sometimes referred to simply as &#8220;FFR Intas&#8221;, which engulfs the activities of contract development, manufacture, biologics, and biosimilars, supported by a solid infrastructure and compliance with regulations worldwide.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The brand-name relation behind <strong>newFFR IntasPharma<\/strong> can be decomposed into the following key points below: what does it mean, why and how it is incorporated into Intas, as well as why it matters to the pharmaceutical markets of 2025.<\/span><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/#What_Is_NewFFR_IntasPharma\" >What Is NewFFR IntasPharma?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/#FFR_Intas_contains\" >FFR Intas contains:<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/#Quality_Assurance_Regulatory_Compliance\" >Quality Assurance &amp; Regulatory Compliance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/#Global_Scope_Strategic_Reach\" >Global Scope &amp; Strategic Reach<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/#Manufacturing_Footprint_Where_and_What_They_Make\" >Manufacturing Footprint: Where and What They Make<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/#Manufacturing_Footprint_Where_and_What_They_Make-2\" >Manufacturing Footprint: Where and What They Make<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/#Strategic_Scope_Global_Reach\" >Strategic Scope &amp; Global Reach<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/#1_E2E_Capabilities_Under_One_Roof\" >1. E2E Capabilities Under One Roof<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/#2_Regulated_Market_Access\" >2. Regulated Market Access<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/#3_Cost-Efficient_Scale\" >3. Cost-Efficient Scale<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/#4_Innovative_Formulation_Tech\" >4. Innovative Formulation Tech<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/#Challenges_Risks\" >Challenges &amp; Risks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/#Future_Outlook_Growth_Drivers\" >Future Outlook &amp; Growth Drivers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/#Conclusion\" >Conclusion<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Is_NewFFR_IntasPharma\"><\/span><b>What Is NewFFR IntasPharma?<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Fundamentally, FFR Intas (Formulation, Finishing, and R&amp;D) is the vertical (or long-term strategic initiative) of the Intas company which provides complete contractual services in the areas of formulation development, manufacturing and development pipelines-especially complex generics and biosimilars\u00a0<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"FFR_Intas_contains\"><\/span><b>FFR Intas contains:<\/b><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Contract Clinical Research and Manufacturing<\/b><span style=\"font-weight: 400;\">: Services provide APIs, biologics and formulations.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Sophisticated Facilities:<\/b><span style=\"font-weight: 400;\"> A state of the art liquids, semi-solids, solid orals, injectables, oncology, and ophthalmics.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Biologics\/Biosimilars Division<\/b><span style=\"font-weight: 400;\">: Nevel bio makes medicine on a monoclonal antibody basis (Filgrastim, Etanercept and others) under EU-GMP certification since 2007\u00a0<\/span><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Quality_Assurance_Regulatory_Compliance\"><\/span><b>Quality Assurance &amp; Regulatory Compliance<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Being in line with the worldwide standards is of paramount importance in the working process of FFR Intas. The division puts an emphasis on:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Raw Material Testing<\/b><span style=\"font-weight: 400;\">: Laboratory measurements to guarantee the high quality of delivered materials.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>In &#8211; process Monitoring: <\/b><span style=\"font-weight: 400;\">Deviation checks in real time in order to uphold the integrity of production.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Finished Product Testing<\/b><span style=\"font-weight: 400;\">: Regulatory parameter checked and validated prior to release of a product into market.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Quality Management System (QMS):<\/b><span style=\"font-weight: 400;\"> On-going auditing, control of processes, integrity of documentation and training<\/span><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Global_Scope_Strategic_Reach\"><\/span><b>Global Scope &amp; Strategic Reach<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Intas uses the new FFR platform to increase world pharma presence.<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>International Reach:<\/b><span style=\"font-weight: 400;\"> More than 22 manufacturing facilities such as those in India, the UK, Greece and Mexico as well as subsidiaries such as Accord Healthcare that are present in North America and Europe\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Biologics\/Biosimilars Strategy:<\/b><span style=\"font-weight: 400;\"> The current partnerships such as Etanercept biosimilar with mAbxience that would provide an exclusive commercialization license in 150+ countries and an accessibility to the global market of USD 11 billion\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>R&amp;D Backbone:<\/b><span style=\"font-weight: 400;\"> A combined force of 400550+ scientists, 50+ patents, and in-house technologies marks the drugs with proprietary technologies like Nanoaqualip 8489 for superior drug-delivery systems\u00a0<\/span><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Manufacturing_Footprint_Where_and_What_They_Make\"><\/span><b>Manufacturing Footprint: Where and What They Make<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ol>\n<li><b> One Roof E2E Competencies:<\/b><span style=\"font-weight: 400;\"> FFR Intas has an end-to-end value chain, including API development, finished dose forms and filing.<\/span><\/li>\n<li><b> Controlled Access to Market:<\/b><span style=\"font-weight: 400;\"> Other markets can be entered using newFFR because of approvals with EU-GMP, GCC, and South Africa, and past activity and progress with FDA.\u00a0<\/span><\/li>\n<li><b> Cost-Efficient Scale<\/b><span style=\"font-weight: 400;\">: There is cost reduction in making production in India, particularly high volume generics and biosimilars.<\/span><\/li>\n<li><b> Advanced Formulation Tech<\/b><span style=\"font-weight: 400;\">: Advancements in technologies such as the patented processes Nanoaqualip TM and NDDS positioning means that newFFR was not just another generic product in the highly competitive generics marketplace<\/span><\/li>\n<\/ol>\n<h2><span class=\"ez-toc-section\" id=\"Manufacturing_Footprint_Where_and_What_They_Make-2\"><\/span><b>Manufacturing Footprint: Where and What They Make<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Intas&#8217;s newFFR platform spans multiple state-of-the-art facilities in India. Here\u2019s a snapshot of their capabilities by location:<\/span><\/p>\n<table>\n<tbody>\n<tr>\n<td><b>Dosage\/Formulation Type<\/b><\/td>\n<td><b>Facility Location(s)<\/b><\/td>\n<\/tr>\n<tr>\n<td><b>Liquid Orals<\/b><\/td>\n<td><span style=\"font-weight: 400;\">Karamsad, Gujarat<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>Semi-Solids<\/b><\/td>\n<td><span style=\"font-weight: 400;\">Vapi, Gujarat<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>Solid Oral Tablets\/Capsules<\/b><\/td>\n<td><span style=\"font-weight: 400;\">Pithampur (MP), Ahmedabad, Matoda (Gujarat), Jammu (J&amp;K)<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>Ophthalmics \/ Injectables \/ Biologics \/ Cytotoxic \/ Oncology<\/b><\/td>\n<td><a href=\"https:\/\/lyncconf.com\/how-intas-pharmaceuticals-newffrintaspharma-is-engaged-in-contract-clinical-research-and-manufacturing\/?utm_source=chatgpt.com\"><span style=\"font-weight: 400;\">Moraiya (Ahmedabad) &amp; Palej (Bharuch), Gujarat<\/span><\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-weight: 400;\">Each facility aligns with <\/span><b>Good Manufacturing Practices (GMP)<\/b><span style=\"font-weight: 400;\"> and quality control via centralized QMS systems.<\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Strategic_Scope_Global_Reach\"><\/span><b>Strategic Scope &amp; Global Reach<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Intas leverages the newFFR platform to enhance its global pharma footprint:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Global Presence<\/b><span style=\"font-weight: 400;\">: Over 22 manufacturing plants\u2014including sites in India, the UK, Greece, and Mexico\u2014plus subsidiaries like <\/span><b>Accord Healthcare<\/b><span style=\"font-weight: 400;\"> operating in North America and Europe.<\/span>&nbsp;<\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Biologics\/Biosimilars Strategy<\/b><span style=\"font-weight: 400;\">: Including partnerships like the Etanercept biosimilar deal with mAbxience, granting exclusive commercialization rights in 150+ countries and exposure to a ~USD 11\u202fbillion global market.<\/span>&nbsp;<\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>R&amp;D Backbone<\/b><span style=\"font-weight: 400;\">: Powered by 400\u2013550+ scientists, 50+ patents, and proprietary technologies such as Nanoaqualip\u2122 for advanced drug-delivery systems.\u00a0<\/span><\/li>\n<\/ul>\n<p><b>Business Advantages: Why Companies Partner with newFFR IntasPharma<\/b><\/p>\n<h3><span class=\"ez-toc-section\" id=\"1_E2E_Capabilities_Under_One_Roof\"><\/span><b>1. E2E Capabilities Under One Roof<\/b><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span style=\"font-weight: 400;\">From API development to finished dosage forms and filing, FFR Intas provides an end-to-end value chain.<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Regulated_Market_Access\"><\/span><b>2. Regulated Market Access<\/b><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span style=\"font-weight: 400;\">With EU-GMP, approvals in GCC, South Africa, and historical steps with FDA, newFFR enables market entry in mature regions.<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Cost-Efficient_Scale\"><\/span><b>3. Cost-Efficient Scale<\/b><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span style=\"font-weight: 400;\">India-based production facilities offer cost savings, especially for high-volume generics and biosimilars.<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_Innovative_Formulation_Tech\"><\/span><b>4. Innovative Formulation Tech<\/b><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Patented processes like <\/span><b>Nanoaqualip\u2122<\/b><span style=\"font-weight: 400;\"> and NDDS positioning differentiates newFFR in the crowded generics market<\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Challenges_Risks\"><\/span><b>Challenges &amp; Risks<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">While newFFR IntasPharma brings strong capabilities, it also grapples with key risks:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Regulatory Setbacks<\/b><span style=\"font-weight: 400;\">: FDA inspections in 2022\u201323 led to warning letters, import alerts, and halted operations at one SEZ site.<\/span>&nbsp;<\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Data Integrity Issues<\/b><span style=\"font-weight: 400;\">: Findings included document shredding and audit trail gaps\u2014both critical red flags in GMP compliance.<\/span>&nbsp;<\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Dependence on Remediation<\/b><span style=\"font-weight: 400;\">: Continued business in the US hinges on successfully implementing remediation plans and regulatory acceptance.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Future_Outlook_Growth_Drivers\"><\/span><b>Future Outlook &amp; Growth Drivers<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li aria-level=\"1\"><b>Biosimilar Push<\/b><b><br \/>\n<\/b><span style=\"font-weight: 400;\">Agreements like Etanercept expand biosimilar margins and pipeline strength.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-level=\"1\"><b>Para IV \/ 505(b)(2) Filings<\/b><b><br \/>\n<\/b><span style=\"font-weight: 400;\"> FFR&#8217;s focus on lifecycle management and complex generics targets high-margin filings in regulated markets.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-level=\"1\"><b>Advanced Drug Delivery<\/b><b><br \/>\n<\/b><span style=\"font-weight: 400;\"> Continued development of NDDS and patented tech will drive niche product strategies globally.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-level=\"1\"><b>Expanded Outsourcing<\/b><b><br \/>\n<\/b><span style=\"font-weight: 400;\"> As global pharma trends toward outsourcing clinical and manufacturing processes, FFR positions Intas as a one-stop solution.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><b>Conclusion<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><b>NewFFR IntasPharma<\/b><span style=\"font-weight: 400;\"> is a formidable component of Intas Pharmaceuticals\u2014leveraging <\/span><b>vertical integration<\/b><span style=\"font-weight: 400;\">, <\/span><b>innovative technologies<\/b><span style=\"font-weight: 400;\">, and <\/span><b>manufacturing scale<\/b><span style=\"font-weight: 400;\"> to compete in global generics and biosimilars. With strong R&amp;D, GMP facilities, and strategic partnerships, it is well-positioned for growth. However, addressing past regulatory issues will be crucial for its long-term success in regulated markets, especially the U.S.<\/span><\/p>\n<p>For pharma companies and investors, newFFR IntasPharma offers an intriguing mix of scale, innovation, and access\u2014but it&#8217;s also a story of risk mitigation and compliance restoration. Tracking its remediation trajectory and future product launches will be key to assessing its global impact.<\/p>\n<p><strong>Read Our More Blogs:-\u00a0\u00a0 <\/strong><strong><a href=\"https:\/\/darkgray-pelican-245271.hostingersite.com\/blogs\/wolf-cut\/\" target=\"_blank\" rel=\"bookmark noopener\">The Wolf Cut: A Fierce Style That Dominates 2025<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>NewFFR IntasPharma is an innovative contract clinical research and manufacturing unit that is the division of an Indian pharma giant, Intas Pharmaceuticals, which has an international presence. This division is [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":31070,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[49],"tags":[1026],"class_list":["post-15675","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-app","tag-newffr-intaspharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NewFFR IntasPharma: A Deep Dive into Intas\u2019s FFR Platform<\/title>\n<meta name=\"description\" content=\"NewFFR IntasPharma is an innovative contract clinical research and manufacturing unit that is the division of an Indian pharma giant,\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NewFFR IntasPharma: A Deep Dive into Intas\u2019s FFR Platform\" \/>\n<meta property=\"og:description\" content=\"NewFFR IntasPharma is an innovative contract clinical research and manufacturing unit that is the division of an Indian pharma giant,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/\" \/>\n<meta property=\"og:site_name\" content=\"JBSA Golf\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-21T04:53:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-27T08:13:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.jbsagolf.com\/blogs\/wp-content\/uploads\/2025\/09\/NewFFR-IntasPharma.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"jbsagolf\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbsagolf\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/newffr-intaspharma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/newffr-intaspharma\\\/\"},\"author\":{\"name\":\"jbsagolf\",\"@id\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/#\\\/schema\\\/person\\\/6846b74cc659c19b62616e6062b3ca8a\"},\"headline\":\"NewFFR IntasPharma: A Deep Dive into Intas\u2019s FFR Platform\",\"datePublished\":\"2025-06-21T04:53:00+00:00\",\"dateModified\":\"2025-10-27T08:13:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/newffr-intaspharma\\\/\"},\"wordCount\":997,\"image\":{\"@id\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/newffr-intaspharma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/NewFFR-IntasPharma.jpg\",\"keywords\":[\"NewFFR IntasPharma\"],\"articleSection\":[\"App\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/newffr-intaspharma\\\/\",\"url\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/newffr-intaspharma\\\/\",\"name\":\"NewFFR IntasPharma: A Deep Dive into Intas\u2019s FFR Platform\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/newffr-intaspharma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/newffr-intaspharma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/NewFFR-IntasPharma.jpg\",\"datePublished\":\"2025-06-21T04:53:00+00:00\",\"dateModified\":\"2025-10-27T08:13:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/#\\\/schema\\\/person\\\/6846b74cc659c19b62616e6062b3ca8a\"},\"description\":\"NewFFR IntasPharma is an innovative contract clinical research and manufacturing unit that is the division of an Indian pharma giant,\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/newffr-intaspharma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/newffr-intaspharma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/newffr-intaspharma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/NewFFR-IntasPharma.jpg\",\"contentUrl\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/NewFFR-IntasPharma.jpg\",\"width\":1280,\"height\":720,\"caption\":\"NewFFR IntasPharma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/newffr-intaspharma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NewFFR IntasPharma: A Deep Dive into Intas\u2019s FFR Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/#website\",\"url\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/\",\"name\":\"JBSA Golf\",\"description\":\"Golf Insights and All-Around Useful Information in One Place.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/#\\\/schema\\\/person\\\/6846b74cc659c19b62616e6062b3ca8a\",\"name\":\"jbsagolf\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ed87e8b0b067f0376363ce00590f815ef81b2bacffe4839651a547fe98dc2be2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ed87e8b0b067f0376363ce00590f815ef81b2bacffe4839651a547fe98dc2be2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ed87e8b0b067f0376363ce00590f815ef81b2bacffe4839651a547fe98dc2be2?s=96&d=mm&r=g\",\"caption\":\"jbsagolf\"},\"url\":\"https:\\\/\\\/www.jbsagolf.com\\\/blogs\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NewFFR IntasPharma: A Deep Dive into Intas\u2019s FFR Platform","description":"NewFFR IntasPharma is an innovative contract clinical research and manufacturing unit that is the division of an Indian pharma giant,","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/","og_locale":"en_US","og_type":"article","og_title":"NewFFR IntasPharma: A Deep Dive into Intas\u2019s FFR Platform","og_description":"NewFFR IntasPharma is an innovative contract clinical research and manufacturing unit that is the division of an Indian pharma giant,","og_url":"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/","og_site_name":"JBSA Golf","article_published_time":"2025-06-21T04:53:00+00:00","article_modified_time":"2025-10-27T08:13:28+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/www.jbsagolf.com\/blogs\/wp-content\/uploads\/2025\/09\/NewFFR-IntasPharma.jpg","type":"image\/jpeg"}],"author":"jbsagolf","twitter_card":"summary_large_image","twitter_misc":{"Written by":"jbsagolf","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/#article","isPartOf":{"@id":"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/"},"author":{"name":"jbsagolf","@id":"https:\/\/www.jbsagolf.com\/blogs\/#\/schema\/person\/6846b74cc659c19b62616e6062b3ca8a"},"headline":"NewFFR IntasPharma: A Deep Dive into Intas\u2019s FFR Platform","datePublished":"2025-06-21T04:53:00+00:00","dateModified":"2025-10-27T08:13:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/"},"wordCount":997,"image":{"@id":"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.jbsagolf.com\/blogs\/wp-content\/uploads\/2025\/09\/NewFFR-IntasPharma.jpg","keywords":["NewFFR IntasPharma"],"articleSection":["App"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/","url":"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/","name":"NewFFR IntasPharma: A Deep Dive into Intas\u2019s FFR Platform","isPartOf":{"@id":"https:\/\/www.jbsagolf.com\/blogs\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/#primaryimage"},"image":{"@id":"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.jbsagolf.com\/blogs\/wp-content\/uploads\/2025\/09\/NewFFR-IntasPharma.jpg","datePublished":"2025-06-21T04:53:00+00:00","dateModified":"2025-10-27T08:13:28+00:00","author":{"@id":"https:\/\/www.jbsagolf.com\/blogs\/#\/schema\/person\/6846b74cc659c19b62616e6062b3ca8a"},"description":"NewFFR IntasPharma is an innovative contract clinical research and manufacturing unit that is the division of an Indian pharma giant,","breadcrumb":{"@id":"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/#primaryimage","url":"https:\/\/www.jbsagolf.com\/blogs\/wp-content\/uploads\/2025\/09\/NewFFR-IntasPharma.jpg","contentUrl":"https:\/\/www.jbsagolf.com\/blogs\/wp-content\/uploads\/2025\/09\/NewFFR-IntasPharma.jpg","width":1280,"height":720,"caption":"NewFFR IntasPharma"},{"@type":"BreadcrumbList","@id":"https:\/\/www.jbsagolf.com\/blogs\/newffr-intaspharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.jbsagolf.com\/blogs\/"},{"@type":"ListItem","position":2,"name":"NewFFR IntasPharma: A Deep Dive into Intas\u2019s FFR Platform"}]},{"@type":"WebSite","@id":"https:\/\/www.jbsagolf.com\/blogs\/#website","url":"https:\/\/www.jbsagolf.com\/blogs\/","name":"JBSA Golf","description":"Golf Insights and All-Around Useful Information in One Place.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.jbsagolf.com\/blogs\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.jbsagolf.com\/blogs\/#\/schema\/person\/6846b74cc659c19b62616e6062b3ca8a","name":"jbsagolf","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/ed87e8b0b067f0376363ce00590f815ef81b2bacffe4839651a547fe98dc2be2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ed87e8b0b067f0376363ce00590f815ef81b2bacffe4839651a547fe98dc2be2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ed87e8b0b067f0376363ce00590f815ef81b2bacffe4839651a547fe98dc2be2?s=96&d=mm&r=g","caption":"jbsagolf"},"url":"https:\/\/www.jbsagolf.com\/blogs\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.jbsagolf.com\/blogs\/wp-json\/wp\/v2\/posts\/15675","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.jbsagolf.com\/blogs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.jbsagolf.com\/blogs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.jbsagolf.com\/blogs\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.jbsagolf.com\/blogs\/wp-json\/wp\/v2\/comments?post=15675"}],"version-history":[{"count":1,"href":"https:\/\/www.jbsagolf.com\/blogs\/wp-json\/wp\/v2\/posts\/15675\/revisions"}],"predecessor-version":[{"id":33793,"href":"https:\/\/www.jbsagolf.com\/blogs\/wp-json\/wp\/v2\/posts\/15675\/revisions\/33793"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.jbsagolf.com\/blogs\/wp-json\/wp\/v2\/media\/31070"}],"wp:attachment":[{"href":"https:\/\/www.jbsagolf.com\/blogs\/wp-json\/wp\/v2\/media?parent=15675"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.jbsagolf.com\/blogs\/wp-json\/wp\/v2\/categories?post=15675"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.jbsagolf.com\/blogs\/wp-json\/wp\/v2\/tags?post=15675"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}